BEIJING, Guangzhou November 6 power (Cai Minjie Zhang Yang ) "Overall, my research is expected to expand immunotherapy for the crowd, and provide a more accurate prediction of the efficacy markers, the appropriate treatment of patients will not miss Opportunities, inappropriate patients will not waste medical expenses and suffer unnecessary side effects
Zhang Yang The National Natural Science Foundation of China announced the final list of winners of the National Science Fund for Distinguished Young Scholars in 2021.
From the National Outstanding Youth Fund in 2016 to the National Outstanding Youth Science Fund in 2021, in the past five years, Su Shicheng led the team to achieve a series of original results in the field of immune microenvironment and immunotherapy.
Tumor immunotherapy won the 2018 Nobel Prize in Medicine and is currently one of the fastest growing cancer treatments
"The first problem is that it is only effective for a small number of patients.
According to reports, anti-PD-1/PD-L1 is currently the most commonly used immunotherapy
"Using the aforementioned immune cell atlas before and after preoperative treatment, we found that the expression of PD-L1 in Her2+ breast cancer before chemotherapy is indeed very low, but after targeted therapy with anti-Her2 antibody, macrophages are phagocytosed by the antibody.
"Our work is to lay a theoretical foundation for the immunotherapy of Her2+ breast cancer, and expand the potential applicable population of breast cancer immunotherapy to three times
"My research direction has always been the comprehensive treatment of breast cancer, with a particular focus on immunotherapy
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
